How Does Epstein-Barr Virus Trigger the Immune Attack Behind Multiple Sclerosis?

TL;DR

Two 2026 studies mapped how Epstein-Barr virus (EBV) drives multiple sclerosis (MS): EBV-specific killer T cells cluster in spinal fluid at up to 100 times blood levels, and immune cells trained against EBV’s viral particles run twice as hot in MS patients. EBV is a required trigger, not the sole cause – genetics and other exposures still shape individual risk.

Key Takeaways

A February 2026 Nature Immunology study found EBV-specific CD8+ T cells concentrated in the cerebrospinal fluid (CSF) of MS patients at 10 to 100 times their levels in blood, pointing to localized immune activity inside the central nervous system.
A July 2026 Science Translational Medicine trial showed CD4+ T cells targeting EBV’s late lytic (viral particle) proteins were twice as active in untreated MS patients as in healthy controls, while EBNA1 (a latent-phase EBV protein) mainly activated CD8+ T cells instead.
B-cell-depleting therapy reduced these EBV-reactive T cell responses and eliminated EBV shedding in saliva, tying the virus’s ongoing activity to the immune overreaction seen in MS.
EBV infection is considered a required trigger for MS, but genetics, vitamin D status, smoking, and obesity all interact with EBV exposure to determine who actually develops the disease.
No EBV vaccine is approved for any use; Moderna’s mRNA-1189 and mRNA-1195 candidates remain in early-phase clinical trials.

Almost every adult carries Epstein-Barr virus (EBV) – by adulthood, roughly 95% of the population has been infected, most without noticing anything beyond a bout of mono. Only a small fraction of those people go on to develop multiple sclerosis (MS), a chronic disease in which the immune system damages the protective myelin sheath around nerve fibers in the brain and spinal cord. For years, researchers knew EBV infection preceded nearly every confirmed MS diagnosis, but the mechanism connecting a nearly universal childhood virus to an autoimmune attack on the central nervous system stayed unclear.

Two studies published in 2026 closed much of that gap. A February 2026 study in Nature Immunology traced where EBV-reactive immune cells physically go once activated, and a July 2026 study in Science Translational Medicine identified which specific parts of the virus those immune cells are trained against. Together, they sketch a plausible sequence: EBV reactivates periodically inside the body, the immune system mounts a disproportionate and persistent response to it, and that response ends up doing damage inside the central nervous system.

What Did the 2026 Studies Actually Find?

How Are EBV-Specific Killer T Cells Showing Up in Spinal Fluid?

Researchers at UC San Francisco ran single-cell RNA sequencing and T cell receptor sequencing on cerebrospinal fluid and blood from treatment-naive MS patients and healthy controls. They identified a small subset of 23 highly expanded, activated CD8+ T cell clonotypes that were enriched almost exclusively in the cerebrospinal fluid of MS patients, not in their blood, and not in either compartment in controls. Six of those clonotypes recognized EBV antigens or related viral mimotopes, and three of the expanded T cell receptors from MS patients reacted specifically to EBV. The team also detected EBV DNA and RNA transcripts directly in the cerebrospinal fluid, including in patients whose EBV-specific CD8+ T cells were the most heavily expanded (Hayashi et al., Nature Immunology, 2026, DOI: 10.1038/s41590-025-02412-3).

That pattern – EBV genetic material and EBV-hunting T cells concentrated together in the fluid bathing the brain and spinal cord – suggests the virus is not just a distant trigger from years earlier. It may be periodically active inside the central nervous system itself, continuously provoking the immune cells that gather there.

Hands loading cerebrospinal fluid sample tubes with a glowing cluster of immune cells visualized above them — EBV-specific CD8+ T cells were found concentrated in cerebrospinal fluid at up to 100 times blood levels.

What Is EBV Training the Immune System to Attack?

A separate research group, publishing in Science Translational Medicine, asked a more specific question: which EBV proteins are these immune cells actually reacting to? Using an optimized T cell assay, they found that CD4+ T cells from MS patients predominantly target EBV’s “late lytic” antigens: capsid and glycoprotein proteins that appear on the virus only when it’s actively replicating, not proteins from EBV’s dormant (latent) state. EBNA1, a protein EBV expresses during latency, instead primarily activated CD8+ T cells. EBV-specific CD4+ T cell responses ran twice as high in untreated MS patients compared with healthy controls, while responses to other herpesviruses stayed similar between the two groups – meaning this wasn’t general immune hyperactivity, but a response focused specifically on EBV.

The same study found that starting anti-CD20 therapy – a B-cell-depleting treatment already used in MS care, since EBV persists inside B cells – reduced these EBV-specific CD4+ T cell responses and eliminated EBV shedding in saliva in treatment-naive participants, a result the researchers validated in an independent patient cohort (Bjornevik et al., Science Translational Medicine, 2026, DOI: 10.1126/scitranslmed.adz6566). That connects the dots: fewer B cells harboring active EBV corresponded with a calmer EBV-specific T cell response.

Why Nerve Tissue Specifically? The Molecular Mimicry Piece

Neither 2026 study fully explains why an immune response built to fight a virus ends up damaging myelin, the fatty insulation around nerve fibers. That piece comes from earlier, well-established research on molecular mimicry: a phenomenon where an immune cell trained to recognize one protein also reacts to a different protein that happens to share a similar structure. A 2022 study found that antibodies targeting EBNA1 cross-react with GlialCAM, a protein expressed on the myelin-producing cells of the central nervous system (Lanz et al., Nature, 2022, PMID: 35073561). In that framework, some of the same immune cells trained against EBV’s latent proteins can mistakenly target the cells responsible for maintaining the nerve sheath, a plausible bridge between the 2026 findings on EBV-specific T cell activity and the nerve damage that defines MS.

Two nearly identical translucent glass sculptural forms, one tinted green and one white, suspended and almost touching — Molecular mimicry: immune cells trained against an EBV protein can also react to a look-alike protein in nerve tissue.

What Factors Shape MS Risk Alongside EBV?

EBV infection is now widely treated as a required trigger for MS – epidemiological data show MS almost never develops without prior EBV infection – but a required trigger is not the same as a sole cause. Roughly 95% of adults carry EBV, and only a small fraction develop MS, which means other variables determine who actually gets sick.

Genetics. Genome-wide association studies have identified more than 230 genetic variants linked to MS susceptibility. Researchers are now studying how these variants interact with environmental exposures, including EBV infection, to shape individual risk rather than acting alone (Jacobs et al., Brain, 2026, DOI: 10.1093/brain/awag111).
Vitamin D status. Mendelian randomization studies support a causal role for low vitamin D in MS risk, and vitamin D deficiency is associated with epigenetic changes at MS-related genetic loci, meaning it may influence how genetic risk gets expressed rather than acting independently.
Smoking and obesity. Both are established modifiable risk factors, with adolescence identified as a particularly sensitive window when the developing immune system responds more strongly to metabolic and environmental triggers (Rival & Thouvenot, Revue Neurologique, 2026, DOI: 10.1016/j.neurol.2026.03.010).
Epigenetic interactions. EBV infection, vitamin D deficiency, and smoking are each associated with epigenetic modifications (chemical changes to how DNA is read, not changes to the DNA sequence itself) at genomic locations already linked to MS risk, offering one mechanistic explanation for how genes and environment combine.

Where Does Monolaurin’s Research Fit Into This Picture?

Monolaurin, a compound derived from lauric acid, has been studied for its ability to physically disrupt the lipid envelope surrounding certain viruses – research has demonstrated this virucidal mechanism against enveloped viruses including HIV-1, yellow fever virus, mumps virus, and Zika virus in laboratory settings (Welch et al., mBio, 2020, DOI: 10.1128/mBio.00686-20). EBV is also a lipid-enveloped virus, which is why it appears in ongoing conversations about monolaurin’s antiviral research – though direct laboratory evidence testing monolaurin specifically against EBV, let alone against its role in MS, has not been established the way it has for the viruses named above. Any interest in monolaurin as part of a broader wellness approach should be paired with realistic expectations about what has and has not been directly studied; readers evaluating monolaurin supplements can review the quality and sourcing criteria at Shop Monolaurin.

Hands resting near a plain supplement bottle and a glass of water on a sunlit kitchen table — Genetics, vitamin D, smoking, and obesity all interact with EBV exposure to shape individual MS risk.

Frequently Asked Questions

Does Epstein-Barr virus cause multiple sclerosis?

EBV infection is considered a required trigger: MS is rarely, if ever, diagnosed in someone who has never been infected with EBV. However, since roughly 95% of adults carry EBV and only a small percentage develop MS, researchers describe EBV as necessary but not sufficient on its own; genetics and other environmental exposures determine individual risk.

If almost everyone gets EBV, why do so few people develop MS?

The 2026 research suggests the difference may lie in how a person’s immune system responds to EBV over time, not just whether they were infected. Genetic variants, vitamin D status, smoking history, and obesity all appear to interact with EBV exposure, and epigenetic changes at MS-related genes may explain part of why the same virus produces such different outcomes in different people.

Is there a vaccine that can prevent EBV from triggering MS?

No EBV vaccine is currently approved for any use. Moderna’s mRNA-1189 candidate is in an early-phase trial in healthy adults (ClinicalTrials.gov NCT07478952), and a related candidate, mRNA-1195, has entered a phase II trial specifically evaluating safety and effects in people with MS. Both remain investigational.

What is molecular mimicry, and how does it connect EBV to nerve damage?

Molecular mimicry describes when an immune cell trained to recognize one protein also reacts to a different, structurally similar protein. Research has shown that immune cells targeting EBV’s EBNA1 protein can cross-react with GlialCAM, a protein found on the cells that maintain the nerve-insulating myelin sheath in the central nervous system, offering one explanation for how an EBV-focused immune response could end up damaging nerve tissue.

Can monolaurin affect Epstein-Barr virus activity?

Monolaurin has documented antiviral activity against several lipid-enveloped viruses in laboratory research, working by disrupting the virus’s outer envelope. EBV shares that lipid-envelope structure, but direct research testing monolaurin against EBV specifically is limited, so any potential effect remains an area for further study rather than an established finding.

What These Findings Mean for Understanding MS

The 2026 research shifts the EBV-MS conversation from correlation to mechanism: EBV-specific immune cells physically concentrate inside the central nervous system, they’re trained against specific viral proteins rather than reacting generically, and reducing the virus’s activity through B-cell-depleting therapy measurably calms that immune response. None of this establishes EBV as the sole explanation for MS: genetics, vitamin D, smoking, and obesity remain active parts of the picture, and no EBV vaccine exists yet to test whether prevention at the infection stage would prevent MS downstream. What the 2026 studies do provide is a clearer map of the immune pathway connecting a virus almost everyone carries to a disease only some people develop.

Continue Exploring

References

Hayashi F, Mittl K, Dandekar R, et al. “Antigen specificity of clonally enriched CD8 T cells in multiple sclerosis.” Nature Immunology. 2026;27(3):490-502. DOI: 10.1038/s41590-025-02412-3
Bjornevik K, Mahler JV, Bilodeau PA, et al. “CD4 T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis.” Science Translational Medicine. 2026;18(858):eadz6566. DOI: 10.1126/scitranslmed.adz6566
Lanz TV, Brewer RC, Ho PP, et al. “Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.” Nature. 2022. PMID: 35073561
Jacobs BM, Vandebergh M, Maltby VE, Dobson R, Kreft KL. “Interplay between genetic and environmental risk factors in multiple sclerosis: what have we learned?” Brain. 2026;149(8):2619-2628. DOI: 10.1093/brain/awag111
Rival M, Thouvenot E. “Non-infectious environmental risk factors of multiple sclerosis: Mechanisms and intervention windows for prevention.” Revue Neurologique. 2026;182(5):455-466. DOI: 10.1016/j.neurol.2026.03.010
Welch JL, Xiang J, Okeoma CM, Schlievert PM, Stapleton JT. “Glycerol Monolaurate, an Analogue to a Factor Secreted by Lactobacillus, Is Virucidal against Enveloped Viruses, Including HIV-1.” mBio. 2020;11(3). DOI: 10.1128/mBio.00686-20
National Institute of Neurological Disorders and Stroke. “Multiple Sclerosis (MS).” ninds.nih.gov
Moderna / ClinicalTrials.gov. “A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults.” NCT07478952